We are live on ! Find out more
ONC icon

BeOne Medicines

220 hedge funds and large institutions have $9.45B invested in BeOne Medicines in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 97 increasing their positions, 65 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more capital inflows, than outflows

Capital inflows: $372M | Capital outflows: $172M

56% more call options, than puts

Call options by funds: $13.2M | Put options by funds: $8.42M

49% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 65

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

2% more funds holding

Funds holding: 215 → 220 (+5)

1.16% more ownership

Funds ownership: 48.2% → 49.36% (+1.2%)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

Holders
220
Holders Change
+5
Holders Change %
+2.33%
% of All Funds
4.5%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
29
Increased
97
Reduced
65
Closed
23
Calls
$13.2M
Puts
$8.42M
Net Calls
+$4.75M
Net Calls Change
-$744K

ONC Hedge Fund Activity: Q2 2020 in Review

220 of the 4,891 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines (ONC) for Q2 2020, worth a combined $9.45B — up 56% from $6.05B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ONC positions and 23 closed out — a net gain of 6 holders — while 97 added to existing stakes and 65 trimmed.

The largest buyer was Capital International Investors, adding an estimated $40.2M. The largest seller was Fidelity Investments, cutting an estimated $44.4M.

  • 220 institutional investors held BeOne Medicines (ONC) as of Q2 2020, up from 215 in Q1 2020.
  • Funds reported $9.45B of BeOne Medicines stock for Q2 2020, up 56% quarter-over-quarter.
  • 29 funds opened new BeOne Medicines positions in Q2 2020 and 23 closed out, a net change of +6 holders.
  • The largest BeOne Medicines buyer in Q2 2020 was Capital International Investors, an estimated $40.2M added.
  • The largest BeOne Medicines seller in Q2 2020 was Fidelity Investments, an estimated $44.4M sold.

Based on aggregated 13F filings for Q2 2020.